COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,886 Articles (22,568 medRxiv, 8,318 bioRxiv)

Most recent first Previous |  Page 858: Articles 8571-8580  | Next

Predictive Model of Risk Factors of High Flow Nasal Cannula Using Machine Learning in COVID-19
Matsunaga, N., Kamata, K., Asai, Y., Tsuzuki, S., Sakamoto, Y., Ijichi, S., Akiyama, T., Yu, J., Yamada, G., Terada, M., Suzuki, S., Suzuki, K., Saito, S., Hayakawa, K., Ohmagari, N.
10.1101/2022.03.02.22271673 — Posted: 2022-03-04
Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers
Del Amo, J.
10.1101/2022.03.02.22271710 — Posted: 2022-03-04
NOVEL RT-qPCR ASSAYS ENABLE RAPID DETECTION AND DIFFERENTIATION BETWEEN SARS-COV-2 OMICRON (BA.1) AND BA.2 VARIANTS
ERSTER, O., Kabat, A., Asraf, H., Levy, V., Mannasse, B., Azar, R., Nemet, I., Kliker, L., Fleishon, S., Mandelboim, M., Mendelson, E., Zuckerman, N. S.
10.1101/2022.02.22.22271222 — Posted: 2022-03-04
Determining the optimal SARS-CoV-2 mRNA vaccine dosing interval for maximum immunogenicity
Asamoah-Boaheng, M., Goldfarb, D. M., Prusinkiewicz, M., Golding, L., Karim, M. E., Barakauskas, V., Wall, N., Jassem, A. N., Marquez, A. C., MacDonald, C., O'Brien, S. F., Lavoie, P., Grunau, B.
10.1101/2022.03.01.482592 — Posted: 2022-03-04
Pegylated-interferon-{lambda} treatment-induced peripheral interferon stimulated genes are associated with SARS-CoV-2 viral load decline despite delayed T cell response in older individuals
Santer, D. M., Li, D., Ghosheh, Y., Zahoor, M. A., Prajapati, D., Tyrrell, D. L. J., Feld, J. J., Gehring, A. J.
10.1101/2022.02.24.22271438 — Posted: 2022-03-03
Z-RNA and the flipside of the SARS Nsp13 helicase
Herbert, A., Shein, A., Poptsova, M.
10.1101/2022.03.03.482810 — Posted: 2022-03-03
Soluble signal inhibitory receptor on leukocytes-1 is released from activated neutrophils by proteinase 3 cleavage
von Richthofen, H. J., Westerlaken, G. H. A., Gollnast, D., Besteman, S., Delemarre, E. M., Rodenburg, K., Moerer, P., Stapels, D. A. C., Andiappan, A. K., Rotzschke, O., Nierkens, S., Leavis, H. L., Bont, L. J., Rooijakkers, S. H. M., Meyaard, L.
10.1101/2022.03.03.482795 — Posted: 2022-03-03
Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays.
Box, H. J., Pennington, S. H., Kijack, E., Tatham, L., Caygill, C. H., Lopeman, R. C., Jeffreys, L. N., Herriott, J., Sharp, J., Neary, M., Valentijn, A., Pertinez, H., Curley, P., Arshad, U., Rajoli, R. K., Rannard, S., Stewart, J. P., Biagini, G., Owen, A.
10.1101/2022.03.03.482788 — Posted: 2022-03-03
SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021.
Mizumoto, K., Shimakawa, Y., Aizawa, Y., Butcher, C., Chibana, N., Collins, M., Kameya, K., Kim, T. G., Koyama, S., Matsuyama, R., Matthews, M. M., Mori, T., Nagamoto, T., Narita, M., Omori, R., Shibata, N., Shibata, S., Shiiki, S., Takakura, S., Toyozato, N., Tsuchiya, H., Wolf, M., Yokoyama, S., Yonaha, S., Takayama, Y.
10.1101/2022.03.02.22271759 — Posted: 2022-03-03
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses
Seaman, M. S., Siedner, M. J., Boucau, J., Lavine, C. L., Ghantous, F., Liew, M. Y., Mathews, J., Singh, A., Marino, C., Regan, J., Uddin, R., Choudhary, M. C., Flynn, J. P., Chen, G., Stuckwisch, A. M., Lipiner, T., Kittilson, A., Melberg, M., Gilbert, R. F., Reynolds, Z., Iyer, S. L., Chamberlin, G. C., Vyas, T. D., Vyas, J. M., Goldberg, M. B., Luban, J., Li, J. Z., Barczak, A. K., Lemieux, J. E.
10.1101/2022.03.02.22271731 — Posted: 2022-03-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).